SMARCE1 and meningioma: The WHO classification incorporates certain molecular alterations associated with meningioma clinicopathologic utility, and the genes affected include: NF2, AKT1, TRAF7, SMO, PIK3CA; KLF4, SMARCE1, BAP1; H3K27me3; TERT promoter, CDKN2A/B in CNS WHO grade 3 (3).